Trials / NCT03316560
Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations
Underway, not enrolling Phase 1 / Phase 2 Gene therapy
- Sponsor
- Beacon Therapeutics
- Treatment
- rAAV2tYF-GRK1-RPGR
- Gene
- RPGR
- Conditions
- X-Linked Retinitis Pigmentosa
- Ages
- 6 Years to 50 Years
- Enrollment
- 29 participants
- Started
- 2018-04-16
- Main results expected
- 2023-11-09
- Results posted
- Not yet
- Record last updated
- 2024-05-20
What the study is testing
This study will evaluate the safety and efficacy of a recombinant adeno-associated virus vector (rAAV2tYF-GRK1-RPGR) in patients with X-linked retinitis pigmentosa caused by RPGR mutations.
Where it runs
United States (4)
- Duke University, Durham, North Carolina
- Cincinnati Eye Institute, Cincinnati, Ohio
- Casey Eye Institute, Portland, Oregon
- Retina Foundation of the Southwest, Dallas, Texas